Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney ; volume:18 ; number:1 ; day:12 ; month:10 ; year:2016 ; pages:1 ; date:12.2016
Arthritis Research & Therapy ; 18, Heft 1 (12.10.2016), 1, 12.2016
- Urheber
-
Miner, Jeffrey N.
- Beteiligte Personen und Organisationen
-
Tan, Philip K.
Hyndman, David
Liu, Sha
Iverson, Cory
Nanavati, Payal
Hagerty, David T.
Manhard, Kimberly
Shen, Zancong
Girardet, Jean-Luc
Yeh, Li-Tain
Terkeltaub, Robert
Quart, Barry
SpringerLink (Online service)
- DOI
-
10.1186/s13075-016-1150-7
- URN
-
urn:nbn:de:1111-201611173168
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Miner, Jeffrey N.
- Tan, Philip K.
- Hyndman, David
- Liu, Sha
- Iverson, Cory
- Nanavati, Payal
- Hagerty, David T.
- Manhard, Kimberly
- Shen, Zancong
- Girardet, Jean-Luc
- Yeh, Li-Tain
- Terkeltaub, Robert
- Quart, Barry
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Gout and uric acid metabolism
Variation in serum urate levels in the absence of gout and urate lowering therapy
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Adherence with urate-lowering therapies for the treatment of gout
Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Gout and uric acid metabolism
Variation in serum urate levels in the absence of gout and urate lowering therapy
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Adherence with urate-lowering therapies for the treatment of gout
Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients
Effects of Conventional Uric Acid–Lowering Therapy on Monosodium Urate Crystal Deposits
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney
Gout and uric acid metabolism
Variation in serum urate levels in the absence of gout and urate lowering therapy
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Adherence with urate-lowering therapies for the treatment of gout
Factors for achieving target serum uric acid levels after initiating urate-lowering therapy in patients with gout: results from the ULTRA registry
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients